Pluto Bioinformatics

GSE114382: First Clinical Study Targeting ROR1, A Cancer Stem Cell Antigen Involved In Rho-GTPase Activation

Bulk RNA sequencing

Cirmtuzumab is a humanized monoclonal antibody that selectively targets ROR1, which is expressed on cancer stem cells (CSCs). Patients experienced reversal of the stemness gene expression signature associated with oncogenic dedifferentiation, inhibition of leukemia-cell activation of Rho-GTPases and HS1, reductions in leukemia cell counts, and prolonged time-to-next-treatment (TTNT) following only 4 biweekly infusions of cirmtuzumab. SOURCE: Emanuela,Maria,Ghia (eghia@ucsd.edu) - University of California San Diego